Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 7/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28508194 | 1.00 | TDP1 (0.56) | TDP1MAOAMAOBDRD2AKT1 | |
| SCHEMBL17738032 | 1.00 | TDP1 (0.56) | TDP1MAOAMAOBDRD2AKT1 | |
| SCHEMBL1449045 | 0.99 | TDP1 (0.54) | TDP1MAOAMAOBDRD2AKT1 | |
| SCHEMBL3154615 | 0.94 | TDP1 (0.51) | TDP1MAOAMAOBDRD2AKT1 | |
| SCHEMBL30269019 | 0.88 | PTGS1 (0.48) | TDP1DRD2AKT1HSP90AA1TLR9 | |
| SCHEMBL998261 | 0.88 | AKT1 (0.59) | TDP1MAOAMAOBDRD2AKT1 | |
| SCHEMBL25934863 | 0.88 | PTGS1 (0.46) | TDP1DRD2AKT1HSP90AA1TLR9 | |
| SCHEMBL25133970 | 0.86 | PLK1 (0.46) | TDP1MAOAMAOBDRD2AKT1 | |
| SCHEMBL30469029 | 0.86 | TDP1 (0.54) | TDP1MAOAMAOBDRD2AKT1 | |
| SCHEMBL25935913 | 0.86 | TDP1 (0.48) | TDP1MAOAMAOBDRD2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637833-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | Genentech, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4469090-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | Genentech Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118591393-A | Antibody conjugated chemical degradation inducers with hydrolyzable maleimide linkers and methods thereof | 基因泰克公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023147328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2016090050-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090040-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090040-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090038-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2015095227-A2 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095223-A2 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-0429611-B1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | ROCHE DIAGNOSTICS GMBH (DE) | 2001-02-28 | — | — | EP | disclosed |
| US-5595741-A | Aminoalkylmaleimides and hapten and antigen derivatives derived therefrom as well as conjugates with peptides or proteins | BOEHRINGER MANNHEIM GMBH (DE) | 1997-01-21 | — | — | US | disclosed |
| EP-0429611-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | Roche Diagnostics GmbH (DE) | 1991-06-05 | — | — | EP | disclosed |
| WO-1990015798-A1 | AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | TDP1 4756/4885MAOA 2231/4885MAOB 3050/4885 |
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | LGMN, B2M, HNMT | TDP1 2839/4885MAOA 3433/4885MAOB 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.